Investment Case
Aedion Therapeutics presents a credible, scientifically grounded opportunity in infectious disease — built for institutional investors, strategic partners, and specialist healthcare funders.
Positioning
Investor Overview
Aedion Therapeutics is a biotechnology company established to build a globally structured dengue therapeutics platform. The company is founded on a simple premise: there is already meaningful scientific and clinical groundwork behind VMD55 — what has been missing is the legal structure, IP strategy, product standardisation, and disciplined development pathway needed to turn that work into a financeable, global asset.
Aedion's role is to consolidate exclusive global rights, secure the associated know-how and supply position, and advance the programme through a credible regulatory and clinical pathway beginning in priority markets. The company is being built to be the institution that transforms pioneering scientific work — including the foundational contribution of Professor Max Reynolds — into a professionally managed therapeutic programme with long-term strategic value.
What makes Aedion compelling is that it combines three features. First, it is highly focused: the company is built around a defined therapeutic opportunity in dengue — a disease with significant regional burden and continued unmet need. Second, it is grounded in substantiated prior clinical work: the predecessor compound to VMD55 completed a Phase III clinical trial in Indonesia, demonstrating significant antiviral activity against dengue virus, a well-characterised safety profile, and capacity to prevent plasma leakage. Third, it is being structured from the outset for protection, execution, and scalability.
In practical terms, Aedion will secure and manage the global exclusive licence for VMD55, protect and expand the intellectual property around the programme, standardise the product to internationally credible quality standards, and generate the regulatory and clinical package needed to unlock the next stage of value creation.
Aedion's ambition is not simply to own an asset. It is to build the leading therapeutics company focused on dengue — and over time, a broader platform in mosquito-borne viral disease.
The predecessor compound to VMD55 has already completed a Phase III clinical trial in Indonesia. The trial demonstrated significant reduction in viral load, confirmed antiviral activity against dengue virus, showed capacity to maintain endothelial homeostasis and prevent plasma leakage, and established a well-tolerated safety profile with no hepatotoxic or nephrotoxic effects. The study concluded the compound was suitable for adoption as standard treatment for dengue patients.
Results pertain to the predecessor compound to VMD55 and do not constitute regulatory approval of VMD55. VMD55 is advancing through an independent regulatory and clinical pathway.
Investment Rationale
Investor Access
A comprehensive overview of Aedion Therapeutics, the VMD55 programme, and the investment case. Prepared for institutional investors and strategic partners considering initial engagement.
Detailed due diligence materials for qualified institutional investors and strategic partners at the formal review stage. Access is individually reviewed and granted following assessment of your request.
Enquiries
Aedion Therapeutics is currently accepting enquiries from institutional investors, strategic partners, and specialist healthcare funders. The team is available to discuss the investment case, programme details, and partnership opportunities.